Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | TUBB4A | P04350 | 3/20 | 0.42 |
| ▸ | TUBB | P07437 | 3/20 | 0.42 |
| ▸ | TUBA3C | P0DPH7 | 3/20 | 0.42 |
| ▸ | TUBA1B | P68363 | 3/20 | 0.42 |
| ▸ | TUBA4A | P68366 | 3/20 | 0.42 |
| ▸ | TUBB4B | P68371 | 3/20 | 0.42 |
| ▸ | TUBB3 | Q13509 | 3/20 | 0.42 |
| ▸ | TUBB2A | Q13885 | 3/20 | 0.42 |
| ▸ | TUBB8 | Q3ZCM7 | 3/20 | 0.42 |
| ▸ | TUBA3E | Q6PEY2 | 3/20 | 0.42 |
| ▸ | TUBA1A | Q71U36 | 3/20 | 0.42 |
| ▸ | TUBA1C | Q9BQE3 | 3/20 | 0.42 |
| ▸ | TUBB6 | Q9BUF5 | 3/20 | 0.42 |
| ▸ | TUBB2B | Q9BVA1 | 3/20 | 0.42 |
| ▸ | TUBB1 | Q9H4B7 | 3/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL796198 | 0.90 | SMO (0.47) | SMN1; SMN2LMNATSHRTUBB4ATUBB | |
| SCHEMBL17220084 | 0.87 | HSD11B1 (0.46) | SMN1; SMN2ALDH1A1TSHRTUBB4ATUBB | |
| SCHEMBL795745 | 0.87 | LMNA (0.42) | SMN1; SMN2LMNATSHRTUBB4ATUBB | |
| SCHEMBL795664 | 0.85 | SMN1; SMN2 (0.43) | SMN1; SMN2TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL796501 | 0.84 | LMNA (0.46) | LMNATSHRALOX15MAPK1 | |
| SCHEMBL15477347 | 0.84 | GAA (0.42) | SMN1; SMN2ALDH1A1LMNATSHRKDM4E | |
| SCHEMBL795712 | 0.84 | NPC1 (0.37) | SMN1; SMN2ALDH1A1TSHRTUBB4ATUBB | |
| SCHEMBL796790 | 0.84 | PRCP (0.40) | SMN1; SMN2LMNATSHRTUBB4ATUBB | |
| SCHEMBL796946 | 0.83 | EPHX2 (0.38) | SMN1; SMN2LMNATSHREPHX2SMO | |
| SCHEMBL17219958 | 0.83 | HSD11B1 (0.41) | SMN1; SMN2ALDH1A1TSHRMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2616465-B1 | TRIAZINE-OXADIAZOLES | NOVARTIS AG (CH) | 2015-11-04 | — | — | EP | disclosed |
| EP-2616465-B1 | TRIAZINE-OXADIAZOLES | NOVARTIS AG (CH) | 2015-11-04 | — | — | EP | disclosed |
| US-20150025057-A1 | Triazine-oxadiazoles | NOVARTIS AG (CH) | 2015-01-22 | — | — | US | disclosed |
| US-20150025057-A1 | Triazine-oxadiazoles | NOVARTIS AG (CH) | 2015-01-22 | — | — | US | disclosed |
| US-20150025057-A1 | Triazine-oxadiazoles | NOVARTIS AG (CH) | 2015-01-22 | — | — | US | disclosed |
| US-8895733-B2 | Triazine-oxadiazoles | NOVARTIS AG (CH) | 2014-11-25 | — | — | US | disclosed |
| US-8895733-B2 | Triazine-oxadiazoles | NOVARTIS AG (CH) | 2014-11-25 | — | — | US | disclosed |
| US-8895733-B2 | Triazine-oxadiazoles | NOVARTIS AG (CH) | 2014-11-25 | — | — | US | disclosed |
| US-20140051676-A1 | Triazine-oxadiazoles | NOVARTIS AG (CH) | 2014-02-20 | — | — | US | disclosed |
| US-20140051676-A1 | Triazine-oxadiazoles | NOVARTIS AG (CH) | 2014-02-20 | — | — | US | disclosed |
| US-20140051676-A1 | Triazine-oxadiazoles | NOVARTIS AG (CH) | 2014-02-20 | — | — | US | disclosed |
| EP-2616465-A1 | TRIAZINE-OXADIAZOLES | Novartis AG (CH) | 2013-07-24 | — | — | EP | disclosed |
| WO-2012035023-A1 | TRIAZINE-OXADIAZOLES | NOVARTIS AG (CH) | 2012-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150025057-A1 | Triazine-oxadiazoles | OPRK1, OPRD1, OPRL1 | SMN1; SMN2 1684/4885ALDH1A1 439/4885LMNA 4798/4885 |
| US-20140051676-A1 | Triazine-oxadiazoles | OPRK1, OPRD1, OPRL1 | SMN1; SMN2 1684/4885ALDH1A1 439/4885LMNA 4798/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.